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Abstract
Background: Brain arteriovenous malformations (BAVM) are clusters of abnormal blood vessels, with shunting of blood
from the arterial to venous circulation and a high risk of rupture and intracranial hemorrhage. Most BAVMs are sporadic, but
also occur in patients with Hereditary Hemorrhagic Telangiectasia, a Mendelian disorder caused by mutations in genes in
the transforming growth factor beta (TGFb) signaling pathway.
Methods: To investigate whether copy number variations (CNVs) contribute to risk of sporadic BAVM, we performed a
genome-wide association study in 371 sporadic BAVM cases and 563 healthy controls, all Caucasian. Cases and controls
were genotyped using the Affymetrix 6.0 array. CNVs were called using the PennCNV and Birdsuite algorithms and analyzed
via segment-based and gene-based approaches. Common and rare CNVs were evaluated for association with BAVM.
Results: A CNV region on 1p36.13, containing the neuroblastoma breakpoint family, member 1 gene (NBPF1), was
significantly enriched with duplications in BAVM cases compared to controls (P = 2.261029); NBPF1 was also significantly
associated with BAVM in gene-based analysis using both PennCNV and Birdsuite. We experimentally validated the 1p36.13
duplication; however, the association did not replicate in an independent cohort of 184 sporadic BAVM cases and 182
controls (OR= 0.81, P = 0.8). Rare CNV analysis did not identify genes significantly associated with BAVM.
Conclusion: We did not identify common CNVs associated with sporadic BAVM that replicated in an independent cohort.
Replication in larger cohorts is required to elucidate the possible role of common or rare CNVs in BAVM pathogenesis.
Citation: Bendjilali N, Kim H, Weinsheimer S, Guo DE, Kwok P-Y, et al. (2013) A Genome-Wide Investigation of Copy Number Variation in Patients with Sporadic
Brain Arteriovenous Malformation. PLoS ONE 8(10): e71434. doi:10.1371/journal.pone.0071434
Editor: Ramani Ramchandran, Medical College of Wisconsin, United States of America
Received January 11, 2013; Accepted June 30, 2013; Published October 3, 2013
Copyright:  2013 Bendjilali et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health (NIH) grants: P01 NS044155 (WLY), R01 NS034949 (WLY), and K23 NS058357 (HK). Additional
support was provided by ‘‘Running for Nona,’’ a private Dutch foundation (CJMK). Control cohorts were supported by NIH grants P50 NS2372 (to E. Mignot) and
U19 AI063603 (to D. Salomon). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: pawlikowskal@anesthesia.ucsf.edu
Introduction
Brain arteriovenous malformations (BAVM) are a tangle of
poorly formed blood vessels with abnormal connections between
arteries and veins, with direct shunting of blood through a vascular
nidus but without an intervening capillary bed. BAVMs are rare,
occurring in less than 1% of the general population, but are a
leading cause of hemorrhagic stroke in children and young adults.
Although the majority of BAVMs arise sporadically, they also
occur in patients with Hereditary Hemorrhagic Telangiectasia
(HHT), a Mendelian disorder inherited in an autosomal dominant
fashion and caused by mutations in one of three genes (ACVRL1,
ENG and SMAD4) in the TGFb signaling pathway [1,2,3,4,5].
Genetic risk factors have been implicated in susceptibility to
non-HHT BAVM [6]. A linkage study in multiplex BAVM
families of Japanese ancestry implicated three loci on chromo-
somes 5, 15 and 18 [7]. Inoue et al [8] performed linkage analysis
in 6 BAVM affected pairs from 6 unrelated families, and reported
suggestive linkage to 7 candidate regions (3q27, 4q34, 6q25, 7p21,
13q32–33, 16p12–13, and 20q11–13) with the strongest support
for 6q25 (LOD=1.88, P= 0.002). Candidate gene studies have
suggested that common variants in ACVLR1 [9], IL1b [10], ITGB8
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[11], and ANGPTL4 [12] are associated with sporadic BAVM.
Finally, several mouse models support the role of genetic
mechanisms in BAVM development [13,14].
Copy number variations (CNVs) represent a significant source
of genetic variation. CNVs, defined as deletions or duplications of
a segment of DNA sequence $1 kb in size compared to a
reference genome, affect roughly 12% of the human genome [15].
De novo CNVs can be a potential genetic mechanism in sporadic
diseases [15]. Recent studies have demonstrated association of rare
and common CNVs with several diseases, including schizophrenia
[16,17,18,19], autism [20,21], and amyotrophic lateral sclerosis
[22,23]. Mechanisms by which CNVs may influence gene function
and thus disease susceptibility include gene dosage imbalances,
altered messenger RNA (mRNA) expression levels or expression of
truncated proteins with altered function [24].
Modern genome-wide arrays include probes for assessing
CNVs, and CNVs can also be called using intensity signals from
single nucleotide polymorphism (SNP) probes. However, accuracy
of the current CNV calling algorithms varies considerably,
yielding substantial false negative and false positive rates [25,26].
A recent study evaluating the performance of five commonly used
CNV calling algorithms concluded that PennCNV and Birdsuite
are superior to others when considering overall reproducibility of
calls and Mendelian consistency [27].
We hypothesized that CNVs (rare or common) may contribute
to sporadic BAVM risk. To obtain reliable CNV calls for
association analysis, we used two algorithms to call CNVs and
focused on CNVs identified by both algorithms significantly
associated with BAVM. Here we present the results of the first
genome-wide association study (GWAS) of CNVs in patients with
sporadic BAVM.
Materials and Methods
Ethics statement
All participants gave written informed consent, and the study
was approved by the Committee on Human Research (CHR) at
the University of California, San Francisco; Kaiser Permanente
Northern California Institutional Review Board for the Protection
of Human Subjects; and the University Medical Center Utrecht
Medical Ethics Review Committee, The Netherlands.
Sample recruitment
The initial cohort included sporadic BAVM patients (n = 371)
recruited at the University of California, San Francisco (UCSF) or
Kaiser Permanente Medical Care Plan of Northern California
(KPNC) as part of a larger UCSF-KPNC Brain AVM registry. Of
the 371 cases, 95 provided saliva and 276 cases provided blood
specimens for DNA extraction. Controls included 216 healthy
controls from a narcolepsy study [28] and 347 transplant donors
from a kidney transplantation study [29]. All control participants
provided blood specimens. Cases and controls were all of self-
reported Caucasian race/ethnicity. The replication cohort com-
prised 184 Caucasian BAVM cases (37 cases from UCSF and 147
cases from the University Medical Center, Utrecht, The Nether-
lands) and 182 healthy Caucasian controls recruited for the Study
Of Pharmacogenetics in Ethnically Diverse Populations (SOPHIE)
[30]. AVM diagnosis, morphological, and clinical characteristics
were recorded using standardized definitions [31,32].
Genotyping
The discovery cohort was genotyped using the Affymetrix
Genome-Wide Human SNP array 6.0 (Affymetrix, Santa Clara,
California), according to the manufacturer’s protocols (http://
www.affymetrix.com); both cases and controls were genotyped in
the same laboratory at UCSF. The Affymetrix 6.0 array contains
906,600 SNP probes and 946,000 CNV probes. Of the CNV
probes, 800,000 are evenly spaced along the genome and the
remaining probes target 3,700 known CNVs [33].
CNV calling and quality control filtering
Pre-CNV calling QC. We discarded samples with more than
5% missing genotypes, or which disagreed on computed and
reported gender. For known or cryptic duplicates, the sample with
the lower genotype call rate was dropped. Overall average
genotyping call rate was 99%. A total of 338 cases and 510
controls passed pre-CNV calling QC filtering.
CNV calling. To identify deletions and duplications for the
22 autosomes, we used the version of the PennCNV algorithm
optimized for CNV calls from the Affymetrix 6.0 array (http://
www.openbioinformatics.org/penncnv/penncnv_tutorial_affy_gw6.
html) and adjusting for genomic waves [34,35]. At each marker,
the B allele frequency (BAF), a measure of the normalized allelic
intensity ratio, and log R ratio (LRR), a measure of the
normalized total signal intensity are used together to infer copy
number state. This algorithm combines these values, the
distance between SNPs, and the population frequency of the
B allele into a hidden Markov model (HMM) to identify
autosomal deletions and duplications. For more precise
modeling of the CNV events, PennCNV adopts a six-state
definition [34]. To ensure reliability of the CNV calls produced
by PennCNV, we also called CNVs using the Birdsuite
algorithm. Birdsuite is a four-stage integrated analysis of SNPs
and CNVs designed specifically for the Affymetrix 6.0 array.
Birdsuite sequentially assigns copy number across regions of
common copy number polymorphisms (CNPs) using Canary
software, then calls SNP genotypes and identifies rare CNVs via
HMM using Birdseye. Finally, copy number and SNP allele
information are combined to provide an integrated genotype at
every locus [36]. The Canary software determines copy number
polymorphisms (CNPs) which are catalogued and present in
more than 1% of 270 HapMap samples [33]. We used results
from PennCNV as our primary findings and focused on top
findings for which PennCNV and Birdsuite gave similar results
as they are more likely to be genuine findings. Previous studies
suggest that PennCNV is one of the optimal algorithms, and the
use of more than one algorithm is highly recommended for
CNV calling to reduce false positive calls [37,38,39].
Post-CNV calling QC. We retained only those CNVs that
were called based on $20 markers in both PennCNV and
Birdsuite (analysis with a$10 marker cutoff yielded similar results,
data not shown). For PennCNV, to reduce the number of false
positives, we removed outliers with respect to the LRR standard
deviation (upper quartile+1.56IQR), BAF-median greater than
0.55 or less than 0.45, BAF-drift .0.005 and waviness factor of
greater than 0.04 or less than 20.04. We also removed samples
that were outliers with respect to the number of CNVs per
individual (.92 CNVs, based on upper quartile+1.56IQR).
For CNVs called by Birdseye, we excluded CNVs with LOD
,10 and samples with high sample-specific measures of noise
(variance .2). CNPs assigned a copy number state equal to 2
(normal) by Canary and those that mapped to the sex
chromosomes were removed. Only CNPs with high confidence
score (,0.1) were included for analysis. The list of common CNPs
generated by Canary was then merged with the list of CNVs
generated by Birdseye into one master file. Samples with an excess
number of CNVs called (.633/sample) were also removed from
downstream analysis. Since CNVs may be artificially split by the
Copy Number Variation in Brain AVM
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CNV calling algorithm, for both PennCNV and Birdsuite,
adjacent calls of the same type were combined into a single
CNV if the gap between the calls was ,20% of the total length of
adjacent calls including the gap region. This resulted in a total of
26,355 CNVs across 270 cases and 457 controls for PennCNV and
27,657 CNVs across 289 cases and 443 controls for Birdsuite.
CNVs overlapping telomeres, centromeres or segmental duplica-
tions were not removed but flagged as these regions are known to
harbor spurious CNV calls. We also explored the results after
excluding CNVs with.50% of their length overlapping segmental
duplications.
Statistical analysis
CNV size was compared between cases and controls using a
two-tailed Mann-Whitney U test because of the non-normality of
the data. We tested association of both rare and common CNVs
with increased risk of BAVM. For tests of association of common
CNVs, we used both a segment-based scoring approach and a
gene-based approach [40,41]. All coordinates are according to the
human NCBI Build 36, hg18 reference sequence. All statistical
analyses, except where otherwise noted, were performed using R
version 2.10.1 software (www.rproject.org).
Segment-based scoring approach
CNV regions (CNVRs) were defined using a segment-based
scoring approach that scans the genome for consecutive markers to
identify loci with significantly more CNVs in cases compared to
controls. Each marker is tested for enrichment of CNVs in cases
versus controls after correcting for multiple testing using a one-
sided Fisher’s exact test; this is done for duplications and deletions
separately. We used principal component analysis (PCA) to model
ancestry differences between cases and controls. PCA was
performed by Eigenstrat v3.0 using SNP genotype calls from
72,456 unlinked markers distributed uniformly across the genome
[42]. To confirm findings from PennCNV, CNVRs were defined
in the same way using Birdsuite calls passing QC filtering. Only
regions passing multiple testing correction using both PennCNV
(adjusted for 91,083 tests for duplications and 80,663 tests for
deletions) and Birdsuite (adjusted for 84,455 tests for duplications
and 63,070 for deletions) were considered for downstream
analysis. Because of the uncertainty in defining CNV boundaries
when using intensity data from SNP arrays, CNVRs are defined
by the union (total length encompassed by both algorithms).
Association of CNVRs with BAVM was assessed by fitting a
multivariate logistic regression model adjusting for age, sex and the
top 3 principal components for population substructure. A CNVR
was considered significantly associated with BAVM if P,1025 in
both PennCNV and Birdsuite. Finally, B allele frequency (BAF)
and log R ratio (LRR) plots were manually examined for top
BAVM-associated loci.
Gene-based approach
We performed a gene-based analysis to assess for significant
enrichment of CNVs overlapping known genes in BAVM cases
compared to controls. This approach identifies CNVs that could
be individually rare, or may disrupt different parts of specific genes
that could be involved in important pathways and contribute to
the etiology of BAVM. In addition, it allows combined analysis of
rare and common CNVs impacting the same gene, thus allowing
evaluation of CNV calls that might be missed by the segment-
based approach.
To test for genes associated with BAVM, we examined CNVs
overlapping genes plus 20 kb upstream and downstream of the
gene boundaries. Significance was assessed using a one-sided
Fisher’s exact test correcting for the 1126 genes overlapping CNVs
from both PennCNV and Birdsuite using the Bonferroni
correction. Deletions and duplications were tested separately.
Rare CNV analysis
To test the hypothesis that cases have a greater burden of rare
large CNVs compared to controls, we performed a burden
analysis, defining burden as either: 1) the total number of CNVs
carried by an individual, or 2) the total number of genes spanned
by those CNVs.
For rare CNV analysis, we only considered CNVs called using
PennCNV and .100 kb. We removed individuals who were
outliers with respect to the total number of CNVs called per
individual and to the total kb span of the CNVs. Finally, common
CNVs (present in .1% of the total sample) were excluded, as well
as CNVs that overlapped by at least 50% of their length with
previously described common CNVs (PLINK software version
1.06) [43]. The final dataset consisted of 732 rare large CNVs
from 437 individuals (158 cases and 279 controls).
The CNVs were further stratified by type (deletions or
duplications) and by size (100–200 kb, 200–500 kb, 500–
1000 kb and .1000 kb). Permutation was used to test if the total
number of CNVs carried by an individual as well as the total
number of genes spanned by those CNVs was significantly higher
in cases compared to controls (PLINK) [43].
Similar analysis was performed for rare CNVs restricting to
each of seven candidate biological pathways relevant to BAVM
based on prior human studies and animal models (TGFb signaling
including the 3 known HHT genes, Notch signaling, Vascular
Endothelial Growth Factor (VEGF) signaling, Angiogenesis,
Vascular Development, Inflammatory Response and Mitogen-
Activated Protein Kinase (MAPK) signaling) [44,45,46,47].
Experimental validation and replication
To validate our top findings, we used several quantitative PCR
(qPCR) assays. First, we used a commercially available probe
(Applied Biosystems, Foster City, CA, Taqman Hs04206910_cn in
NBPF1). qPCR was performed with 10 ng DNA in 10 mL
reactions in triplicate with RNAseP internal reference control on
an ABI7900HT thermocycler. For validation, we assayed 61 cases
from the original cohort and evaluated concordance between copy
numbers estimated by qPCR and by CNV calling algorithms (we
did not have access to DNA from the original controls so we could
not evaluate concordance in controls). For replication, we assayed
184 new BAVM cases (from Utrecht and UCSF) and 182 new
controls. A negative control and at least 2 HapMap Caucasian
reference samples were included on each plate (NA06991,
NA06985 and NA12875). Threshold cycle (CT) values for the
target and the reference generated by qPCR were imported into
CopyCaller software (Applied Biosystems, Foster City, CA). Copy
number of the target sequence was determined by comparing cycle
threshold (CT) between locus probe and internal reference probe
(DDCT) using CopyCaller software (Applied Biosystems, Foster
City, CA). We used the HapMap sample NA06991 as a calibrator
sample.
Second, we designed three custom qPCR probes targeting the
NBPF1 gene (probe 1, 59-CCGAAGCCCTAAATCTCAAC-39
and 59-ACGGCAAGGGACAATTGGCT-39; probe 2, 59-
TTTGTGTCCGGAATGTGCCT-39 and 59- CCCTGCACT-
TACCCTTGTCC-39; probe 3, 59-
TTTCTACCTGGCCCTGGTCT-39 and 59-CCCCAGCTA-
CATTTCATGGCT-39) and assayed them in 177 BAVM cases
from Utrecht (123 cases overlapped the first replication cohort
above). As above, a negative control and at least 2 Caucasian
Copy Number Variation in Brain AVM
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reference samples were included on each plate. Real time qPCR
was performed with 20 ng DNA in 25 mL reactions in triplicate on
an ABI7900HT thermocycler. CNVs were called using the DDCT
method using the average DCT of the total sample as the
reference.
Gene ontology and pathway analysis
The Database for Annotation, Visualization and Integrated
Discovery (DAVID) v6.7b was used for analyzing functional
classification, gene ontology (GO) and pathway analysis (http://
david.abcc.ncifcrf.gov/) for BAVM-specific genes, defined as
genes overlapping at least one CNV in cases and none in controls.
Results
A total of 338 BAVM cases and 510 controls passed array QC.
Cases were significantly younger than controls (mean
age = 38.7 y617.6 y and 50 y614 y respectively, P,0.001).
Gender distribution was similar between cases and controls
(percentage of females: 54.4% cases, 49.8% controls, P = 0.19).
Cases had an average BAVM size of 3 cm61.6 (mean 6 standard
deviation); 16.85% had exclusively deep venous drainage and 38%
presented with hemorrhage.
CNV calling
Using PennCNV, we observed a total of 46,251 raw CNV calls
across 338 BAVM cases and 510 controls, and 26,355 QC-filtered
CNV calls across 270 cases and 457 controls. The average number
of CNVs called per individual was significantly lower in cases
compared to controls (34 vs. 37, P = 3.361029). The overall
median CNV size was significantly larger in cases compared to
controls (40 kb in cases vs. 35 kb in controls, P = 1.2610214). For
duplications, the average number of CNVs per individual did not
differ between cases and controls. For deletions, the average
number of CNVs called per individual was significantly smaller in
cases compared to controls (Table S1); this was also the case for
deletions using Birdsuite. However, for duplications using Bird-
suite, we observed a higher average number of CNVs called per
individual in cases compared to controls (Table S1). Since 26% of
the cases provided saliva specimens for DNA extraction, we also
compared the average number of CNVs called between cases with
saliva specimens and cases with blood specimens. The average
number of duplications called per individual was significantly
higher in cases with blood specimens compared to cases with saliva
specimens (16 vs. 12, P = 4.3161026). For deletions, the average
number of CNVs called per individual did not differ between
blood and saliva DNA.
Segment-based analysis
Using PennCNV, we identified 11 CNVRs (9 duplications,
Figure 1a, and 2 deletions, Figure 1b and Table 1) with
significantly higher frequency in BAVM cases compared to
controls (Fisher’s Exact test after correcting for multiple testing,
P#1.0261025, Table 1). All 11 CNVRs overlapped at least one
copy number locus with a frequency of .1% in the HapMap
population [33]. Among those 11 CNVRs, only one deletion on
chromosome 6 (Figure 1d) passed the correction for multiple
testing using Birdsuite (P = 1.4961029).
Among the 9 duplications passing the correction for multiple
testing using PennCNV, parts of 3 CNVRs on chromosomes 16,
15 and 1 were also identified by Birdsuite (P,261025). CNVRs
were then defined as the union (total length encompassed) of the
CNVRs found by the two algorithms. We further assessed the
association of the 4 CNVR with BAVM using a multivariate
logistic model adjusting for age, sex and the top 3 principal
components of population structure (Table 2). Only one CNVR
on 1p36.13 was significantly associated with BAVM in the
multivariate model using both PennCNV and Birdsuite.
After removing CNVs that overlapped segmental duplication
regions, none of the CNVRs were significantly associated with
BAVM in the multivariate model.
We also evaluated concordance between CNV calls made by
PennCNV and Birdsuite for each CNVR. For the CNVR on
1p36.13, 38 of 105 subjects (36%) called duplications by
PennCNV were also called duplications by Birdsuite. For the
CNVR on 15q11.2, 66 of 149 samples (44%) called duplications
by PennCNV were also called duplications by Birdsuite. For the
CNVR on 16p11.2, 72 of 111 (65%) subjects called duplications
by PennCNV were also called duplications by Birdsuite. For the
CNVR on 6q16.3, only 1/18 samples (6%) were concordant for a
deletion call.
Gene-based analysis
To complement the segment-based analysis with a CNV
analysis that is less sensitive to CNV definition, we performed a
gene-based analysis, including the gene and 20 kb upstream and
downstream. We first examined CNVs in the three HHT genes
(ACVRL1, ENG and SMAD4). None of the CNVs called by
PennCNV overlapped any of the HHT genes in BAVM cases.
We then performed a genome-wide analysis; a total of 1126
genes overlapped CNVs called by both PennCNV and Birdsuite.
Thirty gene transcripts showed significant enrichment of CNVs in
cases compared to controls using PennCNV after correction for
multiple testing (Table 3). Only one gene, OR4K1 (olfactory
receptor, family 4, subfamily K, member 1) was significantly
enriched for deletions in cases compared to controls
(P = 1.1361026); however, this was not supported by Birdsuite
analysis. Among duplications, the NBPF1 gene on chromosome 1
was significantly associated with BAVM in both PennCNV and
Birdsuite (Table 3 and Table S2); NBPF1 is located within the
BAVM-associated CNVR on chromosome 1 from the segment-
based analysis. Figure S1 shows the duplication CNVs called by
PennCNV at 1p36.13 in cases and controls [48]. 486 genes
overlapped CNVs from both PennCNV and Birdsuite after
excluding CNVs with.50% of their length overlapping segmental
duplication regions; none of these genes were significantly
associated with BAVM after correcting for multiple testing.
Rare CNVs
To test the hypothesis that cases have a higher burden of rare
CNVs compared to controls, we examined rare CNVs called from
both PennCNV and Birdsuite. We did not observe a significant
excess of rare large CNVs or genes disrupted in BAVM cases
compared to controls (data not shown).
PennCNV identified 542 genes with CNVs in BAVM cases but
not in controls (CNV overlapping the gene 620 kb). Birdsuite
analysis identified 247 of these 542 genes. However, none of these
genes were significantly associated with BAVM after correction for
multiple testing. Table S3 lists thirteen BAVM-specific genes for
which at least two BAVM subjects and no controls carried CNVs
in both PennCNV and Birdsuite analysis. Eleven genes showed
BAVM-specific deletions, while ATG5 and PRDM1 carried
BAVM-specific duplications.
We also investigated whether BAVM cases carry a greater
burden of rare CNVs overlapping genes in each of 7 candidate
biological pathways relevant to BAVM based on prior studies
(TGFb signaling, Notch signaling, VEGF signaling, Angiogenesis,
Vascular Development, Inflammatory Response and MAPK
Copy Number Variation in Brain AVM
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signaling). These pathways included a total of 572 genes. We did
not observe statistically significant enrichment of rare CNVs in
BAVM cases for any of the candidate pathways (data not shown).
Gene ontology and functional annotation
The Database for Annotation, Visualization and Integrated
Discovery (DAVID) v6.7b was used for analyzing functional
classification, gene ontology of biological processes (GO), and
pathway (http://david.abcc.ncifcrf.gov/) for the 542 genes bearing
BAVM-specific CNVs using PennCNV. Several pathways,
including the chemokine signaling pathway (15 genes,
P = 1.261023, Table S4) were nominally over-represented. In
GO analysis, significantly enriched GO terms included positive
regulation of smooth muscle cell proliferation (Fold enrich-
ment = 9.89 and corrected P=0.02) with a total of 8 AVM-
specific genes (PRKCA, TNF, NOTCH4, ITGA2, EGFR, AGER,
FKBPL and AGPAT1). The molecular function identified as most
significant in GO analysis was cadmium ion binding (fold
enrichment = 29.93, Bonferroni corrected P= 5.7661027, Table
S5).
Experimental validation
To validate the finding that BAVM cases have a higher burden
of CNVs mapping to the 1p36.13 region encompassing the NBPF1
gene compared to controls, we used several qPCR assays. First, we
used a commercial qPCR assay targeting NBPF1 (Applied
Biosystems Taqman Hs04206910_cn). We observed a concor-
dance rate of 78% between CNV states determined by qPCR and
by PennCNV in 51 BAVM cases, including 23 called duplication
and 28 called wildtype by PennCNV. For Birdsuite, we observed a
concordance rate of 52% between Birdsuite calls and qPCR (14
called duplications and 37 called wildtype by Birdsuite). We then
proceeded to replicate the 1p36.13 association with BAVM in an
independent cohort of 184 BAVM cases and 182 healthy controls
utilizing the qPCR assay. In the replication cohort, duplication at
this locus was observed in 13% BAVM cases and 15% of the
controls (OR=0.81, P= 0.8) not supporting the original associa-
tion results. Furthermore, we did not find support for replication
utilizing 3 additional qPCR probes in the NBPF1 gene region.
Three of 177 BAVM cases were called duplications by all 3
probes, a much lower frequency than in the discovery cohort. The
two replication cohorts contained 123 overlapping samples, and
concordance between copy number calls was low (correlation
r2 = 0.4).
Discussion
This is the first genome-wide study to investigate whether CNVs
might be associated with sporadic BAVM susceptibility. We
Figure 1. Plot of CNVR association with BAVM from the segment-based analysis. Chromosomes and -log p-values of CNVR association with
BAVM are shown on the x and the y axes; respectively. The red horizontal line corresponds to the genome wide significance threshold corrected for
multiple testing using the Bonferroni procedure. a. Duplications using PennCNV, b. Deletions using PennCNV, c. Duplications using Birdsuite. d.
Deletions using Birdsuite.
doi:10.1371/journal.pone.0071434.g001
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identified several common CNV loci associated with sporadic
BAVM in our Caucasian cohort of 371 sporadic BAVM cases and
563 controls. We focused on top findings that were in agreement
between two CNV calling algorithms and between gene-based and
segment-based analysis approaches. A BAVM-associated CNVR
mapping to chr 1p36 was experimentally validated using
quantitative real-time PCR, but did not replicate in an indepen-
dent cohort of 184 BAVM cases and 182 controls.
The common BAVM-associated duplication observed at 1p36
encompasses NBPF1, the founding member of the NBPF gene
family that consists of 22 genes and pseudogenes and likely arose
by gene duplication. Very little is known about the function of
NBPF proteins; some of them, including NBPF1, may be tumor
suppressors [49]. Loss of heterozygosity (LOH) for the 1p36 locus
encompassing the NBPF1 gene has been shown in neuroblastoma
and some other tumors [50]. To date, this region has not been
reported to be associated with any vascular diseases or phenotypes.
Our initial association screen also identified other BAVM-
associated CNVR mapping to chr15q11, 6q16 and 16p11.
However, the association with BAVM did not persist in
multivariate models adjusting for age, sex and the top 3 principal
components, utilizing CNV calls from both PennCNV and
Birdsuite. Further, none of these CNVRs overlapped genes
associated with BAVM using the gene-based approach in both
algorithms. The chromosome 15q11.2 CNVR identified in our
study did not overlap the linkage region on 15q11-q13 reported in
non-HHT familial BAVM patients [7]. The small deletion on
6q16.3 showed poor concordance between CNV-calling algo-
rithms and did not overlap any genes. Due to the highly repetitive
Table 1. BAVM-associated CNVRs (PennCNV).
CNVR Length, bp Type Cases Controls OR P* Overlapped genes
chr1: 16,741,950–
16,987,299
245,349 Dup 64 (0.237) 26 (0.057) 5.14 2.70E-12 AL035288,DQ585677, FLJ00313,KIAA0445,
MST1,MSTP9, NBPF1,NBPF10
chr1: 25,465,715–
25,534,799
69,084 Dup 65 (0.241) 36 (0.079) 3.70 2.00E-09 AX747205,RHD
chr4: 2,281–52,126 49,845 Dup 35 (0.130) 13 (0.028) 5.08 2.05E-07 ZNF595,ZNF718
chr9: 68,101,177–
68,126,440
25,263 Dup 17 (0.063) 1 (0.002) 30.53 4.19E-07 AK311167,CR615453, CR626459
chr11: 4,933,069–
4,933,190
121 Dup 49 (0.181) 25 (0.055) 3.82 8.22E-08 OR51A2
chr15: 18,700,552–
18,809,644
109,092 Dup 82 (0.304) 67 (0.147) 2.54 4.62E-07 CR622584,DQ592463
chr16: 32,756,399–
33,638,076
881,677 Dup 62 (0.230) 49 (0.107) 2.48 1.02E-05 BC038215,BC041879, DQ571479,DQ574674,
IGH,IGHV,LOC440366, SLC6A10P,TP53TG3,
TP53TG3b
chr20: 1,508,252–
1,508,999
747 Dup 34 (0.126) 6 (0.013) 10.8 2.03E-10 SIRPB1
chr21: 10,061,090–
10,197,783
136,693 Dup 23 (0.085) 3 (0.007) 14.05 5.26E-08 BAGE,BAGE1, BAGE2,BAGE5
chr6: 103,841,338–
103,841,522
184 Del 17 (0.063) 1 (0.002) 30.53 4.19E-07 None
chr10: 46,478,798–
46,479,827
1,029 Del 56 (0.207) 32 (0.070) 3.47 6.77E-08 ANXA8
*P values are calculated using a one-sided Fisher’s exact test.
doi:10.1371/journal.pone.0071434.t001
Table 2. Multivariate regression model of association of three top CNVRs with BAVM.
PennCNV Birdsuite
CNVR Length Type
No.
probes Cases Controls OR P Cases Controls OR P
chr1: 16,741,950–
17,055,024
313,074 Dup 123 71 (0.263) 34 (0.074) 4.1 2.20E-09 53 (0.18) 14 (0.03) 6.9 2.00E-09
chr15: 18,700,552–
18,809,644
109,092 Dup 18 82 (0.304) 67 (0.147) 2.7 6.55E-07 47 (0.16) 25 (0.06) 3.3 1.37E-05
chr6: 103,841,338–
103,841,522
184 Del 5 17 (0.063) 1 (0.002) 31.3 9.81E-04 31 (0.11) 4 (0.009) 12.9 3.91E-06
chr16: 32,756,399–
33,638,076
881,678 Dup 146 62 (0.23) 49 (0.11) 2.6 1.8E-05 153 (0.53) 199 (0.45) 1.4 3.42E-02
This table summarizes the associated CNVRs with BAVM using a multivariate logistic regression model adjusting for age, sex, and the top three principal components.
doi:10.1371/journal.pone.0071434.t002
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nature of the chr6 and 15 CNVR loci, we were not able to design
qPCR probes for validation.
Although we did not observe a statistically significant association
of rare CNVs with sporadic BAVM in our cohort, given our
limited sample size, we cannot rule out the possibility that rare
CNVs may contribute to BAVM susceptibility. All robust CNV
associations to disease phenotypes that have been reported to date
are with rare CNVs, with the exception of several autoimmune
phenotypes [51,52]. We identified 13 genes bearing BAVM-
specific CNVs in at least 2 BAVM subjects, which are candidates
for replication studies in larger BAVM cohorts. Notably, we did
not identify any BAVM-specific CNVs in the 3 known HHT
genes, in any other genes in the TGFb signaling pathway, or in
genes from 6 other biologically relevant pathways.
Functional classification, GO, and pathway analysis using genes
exclusively deleted or duplicated in cases but not in controls
identified several pathways and GO terms relevant to BAVM
pathogenesis. The most significant pathway was the chemokine
signaling pathway. Significantly enriched GO terms included
positive regulation of smooth muscle cell proliferation and
cadmium ion binding. Interestingly, studies of human vascular
endothelial cells suggest cadmium may alter angiogenesis and
induce apoptosis through VEGF signaling [53].
The size and the average number of CNVs called per individual
differed significantly between cases and controls. In particular,
when restricting to CNVs .10 kb in size, for deletions, the
average number of CNVs per individual was significantly lower in
cases than controls in both PennCNV and Birdsuite. This
difference may be partially explained by differences in DNA
extracted from blood and saliva. In our cohort, all control samples
provided blood while some of the cases provided saliva specimens.
It has been previously reported that CNV analyses differed
between blood and saliva samples for the same individual,
particularly for shorter CNV regions [54]. In contrast to a
Table 3. Genes overlapping BAVM-associated CNVs (PennCNV).
Gene Chr Type Cases Controls
Proportion
Cases
Proportion
Controls OR P (unadjusted)*
P (Bonferroni_
adjusted)**
NBPF10 1 Dup 48 8 0.18 0.02 12.09 8.20E-15 9.23E-12
NBPF1 1 Dup 50 10 0.19 0.02 10.13 2.17E-14 2.44E-11
RHD 1 Dup 65 36 0.24 0.08 3.70 2.00E-09 2.25E-06
C1orf63 1 Dup 64 36 0.24 0.08 3.63 3.95E-09 4.45E-06
TMEM50A 1 Dup 58 36 0.21 0.08 3.19 1.94E-07 2.18E-04
OR4F5 1 Dup 22 6 0.08 0.01 6.65 6.31E-06 7.11E-03
UGT2B15 4 Dup 68 53 0.25 0.12 2.56 2.35E-06 2.65E-03
ZNF595 4 Dup 35 17 0.13 0.04 3.85 4.57E-06 5.15E-03
ZNF718 4 Dup 35 17 0.13 0.04 3.85 4.57E-06 5.15E-03
OR2A1 7 Dup 52 34 0.19 0.07 2.96 2.49E-06 2.80E-03
OR2A42 7 Dup 52 34 0.19 0.07 2.96 2.49E-06 2.80E-03
CTAGE4 7 Dup 53 36 0.20 0.08 2.85 3.85E-06 4.34E-03
OR2A7 7 Dup 53 36 0.20 0.08 2.85 3.85E-06 4.34E-03
OR2A1 7 Dup 52 36 0.19 0.08 2.79 6.80E-06 7.66E-03
OR2A42 7 Dup 52 36 0.19 0.08 2.79 6.80E-06 7.66E-03
LONRF1 8 Dup 10 0 0.04 0.00 Inf 4.49E-05 5.06E-02
CBWD6 9 Dup 17 3 0.06 0.01 10.14 1.17E-05 1.32E-02
FOXD4L6 9 Dup 17 3 0.06 0.01 10.14 1.17E-05 1.32E-02
OR4K1 14 Del 28 9 0.10 0.02 5.75 1.13E-06 1.27E-03
LOC729355 16 Dup 38 11 0.14 0.02 6.62 2.79E-09 3.14E-06
TP53TG3 16 Dup 38 11 0.14 0.02 6.62 2.79E-09 3.14E-06
LOC729355 16 Dup 40 20 0.15 0.04 3.79 1.23E-06 1.38E-03
TP53TG3 16 Dup 40 20 0.15 0.04 3.79 1.23E-06 1.38E-03
LOC729355 16 Dup 40 22 0.15 0.05 3.43 4.49E-06 5.06E-03
TP53TG3 16 Dup 40 22 0.15 0.05 3.43 4.49E-06 5.06E-03
BAGE 21 Dup 23 3 0.09 0.01 14.05 5.26E-08 5.92E-05
BAGE2 21 Dup 23 5 0.09 0.01 8.39 8.74E-07 9.84E-04
BAGE3 21 Dup 23 5 0.09 0.01 8.39 8.74E-07 9.84E-04
BAGE4 21 Dup 23 5 0.09 0.01 8.39 8.74E-07 9.84E-04
BAGE5 21 Dup 23 5 0.09 0.01 8.39 8.74E-07 9.84E-04
*One-sided Fisher’s exact p value.
**P value Bonferroni-adjusted for 1126 genes overlapping CNVs called by both PennCNV and Birdsuite.
Gene-region is defined as gene 620 kb.
Dup= duplication, Del = deletion.
doi:10.1371/journal.pone.0071434.t003
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previous study [55], we identified a statistically significant increase
in the number of CNVs detected in blood DNA specimens
compared to saliva DNA specimens among cases. However, since
case-control differences persisted even when restricting to blood
DNA samples, the difference between saliva and blood DNA
samples does not explain all of the observed effect. Furthermore,
variation in experimental methods including time to genotype all
study cases and controls (,3 years) and batch (i.e., plate) effects
may contribute to the observed case-control differences in the
number of CNVs. While this is a limitation of our study, it would
act as a negative confounder, since the excess of CNV calls was
observed in controls, while the study hypotheses tested for an
excess of CNVs in BAVM cases.
This study is limited by the small sample size, which was not
powered to detect associations with small effect sizes. However,
this is the largest cohort of sporadic BAVM patients for whom
genome-wide genotype data have been analyzed. Further, we have
only explored the role of CNVs in sporadic BAVM subjects of
European ancestry; results may not generalize to other ethnicities.
For the validation experiments, we evaluated the concordance of
CNV states called between PennCNV, Birdsuite and qPCR
among BAVM cases. Unfortunately, we were not able to evaluate
the concordance in the controls used as we do not have access to
their DNA. Since CNV calls from SNP arrays are based on
relative signal intensity of a test sample compared to a reference,
copy numbers in regions overlapping segmental duplications are
highly variable and may not be reliably measured. In fact, copy
number is unlikely to be 2 for a normal sample due to the
repetitive nature of these regions. Our top finding is located in a
region of segmental duplication and it is a known limitation that
CNV calling algorithms may not reliably call CNVs overlapping
segmental duplications, which comprise a large portion of the copy
number variable regions in the human genome (,29% [56]). This
may explain why the association of the chr1p36 duplication with
BAVM did not replicate in an independent cohort.
In conclusion, we provide the first evaluation of the role of
CNVs in sporadic BAVM. We identified several candidate
common CNV loci associated with BAVM, although the top
finding on chromosome 1 did not replicate in an independent
cohort. We also identified a number of genes bearing BAVM-
specific CNVs; however, larger sample sizes are needed to test the
hypothesis that rare CNVs contribute to BAVM pathogenesis.
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